Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Shares Outstanding (Weighted Average) (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $31.1 million as the latest value for Q3 2024.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 18.01% to $31.1 million in Q3 2024 year-over-year; TTM through Sep 2024 was $31.1 million, a 18.01% increase, with the full-year FY2023 number at $26.6 million, up 10.2% from a year prior.
  • Shares Outstanding (Weighted Average) was $31.1 million for Q3 2024 at Actinium Pharmaceuticals, up from $30.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $31.1 million in Q3 2024 to a low of $18.4 million in Q1 2021.
  • A 4-year average of $24.5 million and a median of $24.1 million in 2022 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 20.51% in 2022, then rose 8.52% in 2024.
  • Actinium Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $20.6 million in 2021, then rose by 17.37% to $24.1 million in 2022, then grew by 10.2% to $26.6 million in 2023, then grew by 16.79% to $31.1 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Shares Outstanding (Weighted Average) are $31.1 million (Q3 2024), $30.1 million (Q2 2024), and $27.9 million (Q1 2024).